Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 414 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/26/2007


1.		Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				0 to 18				NCI				CCG-3891 CCG-3891

Last Modified: 3/1/1997


2.		Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma (Summary Last Modified 03/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				no greater than 60				NCI				NU-93B1 NCI-T93-0058D, T93-0058

Last Modified: 4/1/2000


3.		Phase III Randomized Study of MOAB-Purged vs Unpurged Autologous Bone Marrow Following Myeloablative BU/CTX in Adult Acute Myeloid Leukemia in Second Complete Remission (Summary Last Modified 04/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				65 and under				Other				PCI-9404 NCI-V94-0494

Last Modified: 5/8/2007 First Published: 11/1/1994


4.		Phase III Randomized Study of Standard Therapy with ABCM (DOX/BCNU/CTX/L-PAM) vs Intensive Therapy with C-VAMP (CTX/VCR/DOX/MePRDL) Followed by High-Dose L-PAM (with or without TBI) with Hematopoietic Rescue, Both with IFN-A Maintenance, for Previously Untreated Myeloma (Summary Last Modified 03/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 65								MRC-LEUK-MYEL-VII EU-94030, NCT00002599

Last Modified: 1/15/2007


5.		Phase III Randomized Study of ARA-C/DNR vs DHAD/VP-16 Induction Therapy Followed by ARA-C/DNR Consolidation Therapy in Older Patients with Previously Untreated Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				56 and over				NCI				SWOG-9333 SWOG-9333

Last Modified: 3/1/1997


6.		Phase III Randomized Study of Rescue with CD34+ Selected vs Unselected Autologous PBSC Following High-Dose BU/CTX for Multiple Myeloma (Summary Last Modified 03/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 70				Pharmaceutical / Industry				CP-0060-002 NCI-V95-0712

Last Modified: 8/10/2006


7.		Phase III Randomized Study of Induction With the ALL-2 Regimen (Cytarabine and High-Dose Mitoxantrone Based) Versus the L-20 Regimen (Vincristine and Prednisone Based) in Adults With Acute Lymphoblastic Malignancy: The ALL-4 Protocol

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				MSKCC-96015A1 NCI-V96-0881, NCT00002766

Last Modified: 10/22/2007 First Published: 6/1/1997


8.		Phase III Study of Dactinomycin and Vincristine With or Without Cyclophosphamide and/or Radiotherapy in Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma of Embryonal or Botryoid Subtype

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Under 50				NCI				COG-D9602 CCG-D9602, POG-D9602, IRS-D9602, D9602, NCT00002995

Last Modified: 12/6/2007 First Published: 8/1/1997


9.		Phase III Study of Early High-Dose Chemoradiotherapy and Autologous Peripheral Blood Stem Cell Transplantation Versus Conventional Dose Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Intermediate- or High-Grade Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 65				NCI				SWOG-S9704 CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11

Last Modified: 8/3/2007 First Published: 12/1/1997


10.		Phase III Study of Combination Chemotherapy in Children With Intermediate-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Under 21				NCI				COG-A3961 CCG-A3961, POG-A3961, NCT00003093, A3961

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute